Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of PIT565 in Rheumatoid Arthritis
NCT07029555Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2025
- Primary completion
- May 2028
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of PIT565 in rheumatoid arthritis (RA) (8 arms), sponsored by Novartis. Primary endpoint: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) at 6 months. Started Jun 2025; status: active, not recruiting.
02
Drugs
PIT565
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07029555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029555.